drugset / Trial / NCT05075408
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.
Timeline
- Start
- 2022-03-18
- Primary completion
- 2024-01-04
- Completion
- 2024-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | 30 mg | Subcutaneous |
Indications
No indication recorded.